Clinical Development & Data
Trial architecture, endpoints, recruitment, comparator signals, investigator interpretation, and the way evidence in gastroenterology will be read downstream.
Gastroenterology
ICG works across gastroenterology environments where clinical sequencing, biomarker use, specialist pathways, chronic administration, access, and patient-support systems interact.
The work includes gastroenterology competitive intelligence, IBD development and launch, short-bowel syndrome, pancreatic-enzyme replacement, motility markets, biosimilars, delivery systems, and longitudinal monitoring.
Chronic Pathways, Multiple Points of Friction.
Gastroenterology assets enter pathways shaped by treatment sequencing, specialist practice, biomarkers, route of administration, persistence, reimbursement, and the organization of long-term care.
ICG reconstructs those conditions across clinical development and commercial reality to identify the dependencies governing differentiation and adoption.
Decision Environments
Engagements begin at different points, but the governing constraints often cross the boundaries of the initial request.
Regulatory & Access Pathways
Filing logic, label conditions, evidence requirements, reimbursement, pathway position, and country-level adoption constraints.
Launch & Commercial Architecture
Market preparation, field-force and medical roles, account coverage, channel structure, patient support, and launch sequencing.
Manufacturing & Delivery
Capacity, supply, configuration, administration, device or site readiness, and the relationship between operational uncertainty and asset value.
Patient & Treatment Systems
Patient identification, referral patterns, specialist pathways, administration burden, monitoring, persistence, and continuity of treatment.
Longitudinal Competitive Monitoring
Clinical, regulatory, access, organization, and commercial signals reconstructed across multi-phase and multi-year programs.
Evidence Architecture
The evidence base is developed through source calls and interviews positioned close to the decisions, constraints, and operating conditions being reconstructed.
Clinical & Investigator Side
Key opinion leaders, principal investigators, study-site personnel, treating specialists, centers of excellence, diagnostic pathways, and investigator-side clinical teams.
Company-Side Sources
Clinical development, regulatory, medical affairs, CMC and manufacturing, market access, patient services, field leadership, commercial, and portfolio functions.
Access & Operating Systems
Payer and reimbursement environments, procurement, distribution, treatment centers, testing providers, administration systems, patient-support infrastructure, and local access pathways.
Triangulation
Interview evidence is tested against clinical, regulatory, manufacturing, access, and organizational signals and against the criteria used by reviewers, payers, clinicians, partners, and other decision-makers.
Selected Project Record
Selected engagements across gastroenterology.
The projects below are selected from a substantially larger body of work. They were chosen to illustrate different decision environments, lifecycle stages, modalities, geographies, and forms of engagement. The selection is illustrative rather than exhaustive. Multi-phase and longitudinal assignments may be presented as a single project title, and company, asset, or market details may be generalized where appropriate.
Clinical Development & Data
- Launch and Competitive Assessment of IL-23 and JAK Therapies in Crohn's Disease
- Clinical and Commercial Development Assessment of GLP-2 Therapies in Short Bowel Syndrome
- Clinical-Development Assessment of Therapies in Celiac Disease
- Biomarker and Trial-Pathway Assessment in Inflammatory Bowel Disease
Regulatory, Access & Adoption
- Market-Access and Commercialization Architecture for Chronic Constipation and IBS-C Therapies in the United States and Europe
- Reimbursement and Treatment-Pathway Assessment for Short-Bowel-Syndrome Therapies
- Market-Access Assessment for Pancreatic-Enzyme Replacement Therapies in Selected Countries of Eastern Europe
- Payer and Specialist Adoption of Biologics in Crohn's Disease
Launch & Commercial Architecture
- Launch Architecture for Advanced Therapies in Inflammatory Bowel Disease
- Commercial and Field-Organization Assessment in Chronic GI Disorders
- Home-Administration Device Landscape for Crohn's Disease
- Commercialization Assessment for Gastrointestinal Motility Therapies
Manufacturing, Delivery & Systems
- Manufacturing and Cost Assessment for Pancreatic-Enzyme Replacement Therapy
- Delivery-System Assessment for Biologics in Inflammatory Bowel Disease
- Patient-Support and Administration Architecture in Short Bowel Syndrome
Longitudinal Monitoring & Portfolio
- Multi-Year Commercial and Market-Access Monitoring for Pancreatic-Enzyme Replacement Therapy in Selected Countries of Eastern Europe
- Longitudinal Monitoring of Advanced Therapies in Inflammatory Bowel Disease
- Portfolio Monitoring Across Short Bowel Syndrome, Motility and Pancreatic Insufficiency
Gastroenterology Engagements
ICG can enter at the level of a single critical question, a multi-market evidence program, or a longitudinal clinical, regulatory, manufacturing, access, commercial, or operating-system decision environment.